1. Home
  2. REVB vs FAMI Comparison

REVB vs FAMI Comparison

Compare REVB & FAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • FAMI
  • Stock Information
  • Founded
  • REVB 2020
  • FAMI 2015
  • Country
  • REVB United States
  • FAMI China
  • Employees
  • REVB N/A
  • FAMI N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • FAMI Packaged Foods
  • Sector
  • REVB Health Care
  • FAMI Consumer Staples
  • Exchange
  • REVB Nasdaq
  • FAMI Nasdaq
  • Market Cap
  • REVB 2.3M
  • FAMI 2.1M
  • IPO Year
  • REVB N/A
  • FAMI 2018
  • Fundamental
  • Price
  • REVB $0.85
  • FAMI $1.56
  • Analyst Decision
  • REVB
  • FAMI
  • Analyst Count
  • REVB 0
  • FAMI 0
  • Target Price
  • REVB N/A
  • FAMI N/A
  • AVG Volume (30 Days)
  • REVB 118.3K
  • FAMI 10.5K
  • Earning Date
  • REVB 11-06-2025
  • FAMI 01-26-2026
  • Dividend Yield
  • REVB N/A
  • FAMI N/A
  • EPS Growth
  • REVB N/A
  • FAMI N/A
  • EPS
  • REVB N/A
  • FAMI N/A
  • Revenue
  • REVB N/A
  • FAMI $43,831,754.00
  • Revenue This Year
  • REVB N/A
  • FAMI N/A
  • Revenue Next Year
  • REVB N/A
  • FAMI N/A
  • P/E Ratio
  • REVB N/A
  • FAMI N/A
  • Revenue Growth
  • REVB N/A
  • FAMI N/A
  • 52 Week Low
  • REVB $0.84
  • FAMI $1.39
  • 52 Week High
  • REVB $60.48
  • FAMI $7.07
  • Technical
  • Relative Strength Index (RSI)
  • REVB 24.56
  • FAMI 37.93
  • Support Level
  • REVB $0.84
  • FAMI $1.40
  • Resistance Level
  • REVB $1.08
  • FAMI $1.58
  • Average True Range (ATR)
  • REVB 0.08
  • FAMI 0.06
  • MACD
  • REVB -0.01
  • FAMI 0.00
  • Stochastic Oscillator
  • REVB 5.77
  • FAMI 30.97

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.

Share on Social Networks: